An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 02 Apr 2018
At a glance
- Drugs TRC 253 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors TRACON Pharmaceuticals
- 28 Feb 2018 According to a TRACON Pharmaceuticals media release, dose escalation portion is expected to complete in mid-2018.
- 10 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium
- 05 Feb 2018 Planned end date changed from 1 Oct 2018 to 1 Jun 2019.